An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-002014-22-HU

Enrollment

Registered

2014-05-16

Start date

2014-05-27

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced ovarian cancer MedDRA version: 17.0 Level: PT Classification code 10057529 Term: Ovarian cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Product Name: Olaparib Pharmaceutical Form: Capsule, hard CAS Number: 763113-22-0 Other descriptive name: OLAPARIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histological proven ovarian cancer Advanced cancer ECOG 0-3 Appropriate laboratory functions Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Main Objective: Progression free survival;Secondary Objective: Overall survival;Primary end point(s): Progression of cancer ;Timepoint(s) of evaluation of this end point: -	—

Secondary

Measure	Time frame
Secondary end point(s): Progression of cancer ;Timepoint(s) of evaluation of this end point: -	—

Countries

Hungary

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026